Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

被引：0
|
作者：
Collins, Peter [1 ]
Faradji, Albert [2 ]
Morfini, Massimo [3 ]
Enriquez, Monika Maas [4 ]
Gorina, Eduard [5 ]
Schwartz, Lawrence [6 ]
Lemm, Georg [5 ]
机构：
[1] Univ Wales Hosp, Cardiff CF4 4XW, S Glam, Wales
[2] Hautepierre Hosp, Strasbourg, France
[3] Univ Hosp, Florence, Italy
[4] Bayer HealthCare, Wuppertal, Germany
[5] Bayer HealthCare Pharmaceut, Berkeley, CA USA
[6] Bayer HealthCare Pharmaceut, Montville, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：194 / 195
页数：2
相关论文
共 33 条
  • [21] Six-month clinical observation on safety and efficacy of a full-length recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A
    Zhang, L.
    Zhao, Y.
    Sun, J.
    Wang, X.
    Wu, J.
    Yu, M.
    Yang, R.
    HAEMOPHILIA, 2011, 17 (03) : 538 - 541
  • [22] Consequences of Switching From Prophylactic Treatment to On-Demand Treatment in Late Teens and Early Adults with Severe Hemophilia A. the TEEN/TWEN Study
    Manco-Johnson, Marilyn J.
    Sanders, Joann
    Ewing, Nadia
    Humphries, Thomas J.
    BLOOD, 2011, 118 (21) : 993 - 993
  • [23] Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate®) and BAY 81-8973 (KovaltryA®) in patients with severe or moderate haemophilia A in prophylaxis
    Eduardo Megias-Vericat, Juan
    Bonanad, Santiago
    Haya, Saturnino
    Rosa Cid, Ana
    Remedios Marques, Maria
    Monte-Boquet, Emilio
    Perez-Alenda, Sofia
    Bosch, Pau
    Querol, Felipe
    Luis Poveda, Jose
    HAEMOPHILIA, 2019, 25 (03) : E215 - E218
  • [24] Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children
    Chozie, Novie A.
    Primacakti, Fitri
    Gatot, Djajadiman
    Setiabudhy, Rahajuningsih D.
    Tulaar, Angela B. M.
    Prasetyo, Marcel
    HAEMOPHILIA, 2019, 25 (04) : 633 - 639
  • [25] Study design of 2 randomized, crossover, open-label trials to evaluate the pharmacokinetics, efficacy, and safety of plasma protein-free recombinant factor VIII formulated with sucrose (BAY 81-8973) in previously treated patients with severe hemophilia A
    Kavakli, K.
    Saxena, K.
    Enriquez, M. Maas
    HAEMOPHILIA, 2012, 18 : 25 - 25
  • [26] Effect on Joint Health of Routine Prophylaxis with Bayer's Sucrose-Formulated Recombinant Factor VIII (rFVIII-FS) in Adolescents and Adults Previously Treated on Demand: MRI Analyses from the 3-Year Spinart Study
    Lundin, Bjorn
    Hong, Walter
    Raunig, David
    Engelen, Sylvia
    Peterfy, Charles
    Werk, Michael
    Manco-Johnson, Marilyn J.
    BLOOD, 2014, 124 (21)
  • [27] Safety and efficacy of plasma/albumin-free recombinant factor VIII for the treatment of previously treated patients with hemophilia A in China: a 6 month compassionate use study
    Yang, R.
    Zhao, Y.
    Sun, J.
    Wang, X.
    Yu, M.
    HAEMOPHILIA, 2010, 16 : 32 - 33
  • [28] Efficacy and Safety of Third-Generation Full Length Recombinant Human Coagulation Factor VIII in the Standard Prophylactic Treatment of Childhood Patients with Moderate-to -Severe Hemophilia A: A Single Center Experience
    Zhou, Rong-Fu
    Li, Qian
    Ouyan, Jian
    Zhou, Min
    Chen, Bing
    Xu, Yong
    Li, Ping
    BLOOD, 2017, 130
  • [29] 3-Year Analyses From SPINART: Patient- and Joint-Level Changes in Magnetic Resonance Imaging Scores With Bayer's Sucrose-Formulated Recombinant Factor VIII (RFVIIIFS) in Adolescents and Adults Previously Treated on Demand
    Lundin, B.
    Hong, W.
    Raunig, D.
    Engelen, S.
    Peterfy, C.
    Werk, M.
    Manco-Johnson, M. J.
    HAEMOPHILIA, 2015, 21 : 40 - 41
  • [30] Pharmacokinetic results and correlations with intrinsic von Willebrand factor levels from a randomized, double-blind study of prophylaxis with once-weekly BAY 79-4980 vs. 3-times-weekly sucrose-formulated recombinant factor VIII
    Martinowitz, U.
    Windyga, J.
    Powell, J.
    Enriquez, M. Maas
    Scharrer, I.
    HAEMOPHILIA, 2012, 18 : 25 - 25
1234